For example, individuals receiving placebo may not experience satisfactory weight loss and as a result may adopt another behavioral measure or weight-loss medication (other than the active medication) during the trial, and thus experience a larger reduction in body weight than if they had only received placebo
Cardiovasc Diabetol 22(1):49 Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial
How GLP-1 pricing works Costs can vary based on insurance, eligibility and medication type
GLP-1 drugs may reduce: Frequency of drinking Volume per occasion Desire to drink What this means across the three-tier system Suppliers Monitor changes in premium product demand Evaluate opportunities in lower-ABV and alternative beverages Distributors Watch for shifts in order frequency and product mix Identify regional differences tied to demographics and health trends Retailers On-premise: fewer drinks per visit Off-premise: smaller baskets and substitution effects Why this is a data problem If youre in beverage alcohol, this is a trend you wont see in your dashboardbut you will see it in your data
